Direct answer
The reviewed acute studies do not establish monk-fruit-specific diabetes treatment, weight loss or a safest form. The 30-person Tey trial had lower first-hour but higher post-lunch glucose and insulin responses, with no significant three-hour total difference; insulin was measured in ten participants. JECFA’s 2026 temporary ADI is 0–10 mg/kg body weight/day as mogroside V, with further data required. Regulatory conclusions apply to specified preparations and uses. Reported support and unresolved financial or product-supply gaps remain explicit.
- The human studies reviewed here do not establish a safest monk-fruit form. They assess specific preparations and short-term outcomes (acute crossover study; acute diabetes-group comparison). Ireland’s October 2024 decision treats specified non-selective aqueous decoctions as not novel based on pre-1997 UK food consumption; this is not approval of every liquid extract or a comparative safety ranking (FSAI decision).
- Monk fruit (Siraitia grosvenorii, or luo han guo) is used in extract powders, liquid preparations and blends. In Hunan NutraMax’s GRN 629 manufacturer submission, MV 7 through MV 95 designate minimum mogroside V percentages in its ingredient powders. These are not the percentages of every liquid product or finished retail blend.
- The reviewed acute beverage studies do not establish a monk-fruit-specific diabetes treatment. Replacing a large sugar load differs from demonstrating sustained glucose control (three-hour trial; 24-hour study; diabetes-group trial).
- The reviewed clinical studies do not establish sustained weight loss, antioxidant benefit or safety of concentrated supplementation during pregnancy. This is graded Insufficient; it is not proof that an exhaustive search found no human research (acute study; literature map).
- FDA has not questioned GRAS conclusions for certain monk fruit ingredients under their notified conditions of use (FDA explanation). It ceased evaluating GRN 629 after withdrawal to change product profiles/specifications; GRN 627 received a no-questions response for a specific fruit juice concentrate. Neither outcome is blanket FDA approval of every extract or retail product.
- The 2023 bibliometric analysis maps 155 publications and identifies substantial animal and laboratory work. Such studies can explain mechanisms but do not establish human clinical benefit. Toxicological animal evidence can still inform regulatory safety assessment (JECFA 2026).
- In June 2026, JECFA set a temporary ADI of 0–10 mg/kg body weight/day, expressed as mogroside V. Its conservative child-exposure scenario under proposed food categories and maximum levels exceeded this limit; see the safety FAQ for scope and data gaps (WHO evaluation).
Table of contents
- Evidence summary
- What monk fruit is
- Forms and ingredient grades
- Interactions and evidence gaps
- Who should seek advice first
- How laboratory evidence is used
- Funding, conflicts and source roles
- Frequently asked questions
- Sources and funding notes
| Claim | Evidence | Source | Funding/conflict | Strength |
|---|---|---|---|---|
| Monk-fruit-specific diabetes treatment | The reviewed acute comparisons do not test long-term HbA1c control or clinical diabetes outcomes | Tey 2017, 24-hour glucose; Lavalle-Gonzalez 2023 | Tey: Singapore Institute for Clinical Sciences/A*STAR, no conflicts declared. Diabetes trial: funding unreported, no competing interests declared | Not established by these protocols |
| Claims of specific glucose/insulin percentage benefits | The 2025 review’s headline ranges are unreliable: its trial descriptions and references disagree with the originals | Kaim and Labus 2025; original acute trial | Review: no external funding/no conflicts declared; these declarations do not resolve the evidence discrepancies | Do not use its 10–18% or 12–22% ranges as verified effects |
| Acute glucose/insulin response versus a sucrose preload | 30 healthy lean men; glucose measured in 30, insulin in 10. Noncaloric preloads produced lower first-hour but higher post-lunch responses; total three-hour glucose/insulin AUC did not significantly differ | Tey 2017, International Journal of Obesity | Singapore Institute for Clinical Sciences/A*STAR; no conflicts declared. Ingredient supplier/payment terms unreported | One-day crossover; not sustained glucose improvement or equivalence |
| 24-hour glucose after one beverage | Ten healthy lean men; no significant differences in mean glucose, AUC or variability among monk fruit, stevia, aspartame and sucrose beverages | Tey 2017, European Journal of Clinical Nutrition | Singapore Institute for Clinical Sciences/A*STAR; no conflicts declared. Same registered protocol as the IJO report; overlap not separately reconstructed | Small acute study; nonsignificance does not prove equivalence |
| Acute response to monk fruit versus a large sugar load | 26 adults with T2DM and 29 without diabetes, two visits. Lower glucose with 0.51 g monk fruit preparation versus a 75 g load; insulin assessed only in ten non-diabetic controls | Lavalle-Gonzalez 2023 | Funding unreported; no competing interests declared. Product grade/supplier unspecified; comparator called glucose in methods and sucrose elsewhere | Different carbohydrate loads; not a glucose-lowering drug test, diabetic-insulin benefit or long-term safety finding |
| Weight-management benefit | The acute IJO study found no significant total daily energy-intake difference; it did not measure sustained weight loss | Original one-day crossover | Institute/A*STAR support; later intake self-reported | Long-term weight benefit not established here |
| Antioxidant benefit in humans | The literature map describes preclinical mechanisms; it is not a pooled clinical antioxidant-efficacy assessment | Yeung 2023 bibliometric analysis | Departmental funds only; no commercial/financial relationships declared | Human benefit not established by this source |
| Pregnancy supplementation safety | The reviewed acute studies do not establish pregnancy safety; JECFA requests reproductive-capacity data to complete its safety evaluation | Clinical population; JECFA 2026 summary | Diabetes study excluded pregnancy; regulatory assessment is a separate evidence role | Concentrated supplementation safety not established; food rules are preparation-specific |
What monk fruit is
Monk fruit is Siraitia grosvenorii, a climbing plant in the gourd family whose fruit is traditionally used in foods and herbal preparations. Mogrosides, particularly mogroside V, provide intense sweetness (botanical review). This does not make every fruit preparation sugar-free: the specific juice concentrate in GRN 627 contains substantial natural sugars. Extract powders, juice concentrates and diluted blends differ in composition.
Monk fruit occurs in subtropical China, including Guangxi, Guizhou, Hunan, Guangdong and Jiangxi. Yongfu and Longsheng in Guilin are important cultivation areas (Guo 2024 review). Genetic sampling of 130 wild and 21 cultivated individuals supports a Guilin origin for the sampled cultivars (Xie 2023 phylogeographic study); it is not a current census of global extract manufacturing.
Forms and ingredient grades
The examples below distinguish ingredient powders, diluted preparations and blends. Product concentration, other ingredients and label directions matter; a mogroside grade is not an efficacy, purity-of-the-whole-product or safety ranking.
| Form | Mogroside V content / grade | Sweetness vs. sucrose | Typical use | Notes |
|---|---|---|---|---|
| Monk fruit extract powder | The SweetMonk submission lists minimum mogroside V grades from ≥7% to ≥95% | FDA’s general description reports 100–250-fold sweetness, depending on composition (FDA explanation) | Ingredient for food/tabletop formulation | Company-specific specifications, not an approval or universal grade system (GRN 629 dossier; withdrawal letter) |
| Liquid preparations | Extract diluted in a liquid carrier; actual mogroside V content must come from its specifications | Depends on concentration and formulation | Beverages/tabletop use where permitted | Do not infer that all drops are standardised, contain no sugar or fall under the Irish decoction decision |
| Erythritol blends | Monk fruit ingredient plus erythritol and any other labelled ingredients | Product-specific; follow its substitution directions | Tabletop or baking use where intended | A blend’s bulk, tolerability and nutrition cannot be attributed to monk fruit alone |
| Granulated blends | Monk fruit ingredient with a bulking agent; composition varies | Sweetness, texture and recipe behaviour depend on the complete formulation | Recipe substitution when labelled for it | Sugar-like sweetness does not guarantee sugar-like browning, structure or other baking behaviour |
| Fruit juice concentrate | GRN 627 describes a specific concentrate with 3.5% mogroside V, 56% sugars and 35% water | Not interchangeable with a highly purified powder | Specific food uses described in the notice | FDA had no questions about the notifier’s GRAS conclusion under intended conditions; not every traditional decoction (agency letter) |
The NutraMax submission describes fresh-fruit water extraction followed by resin, ethanol and chromatographic purification. Manufacturing varies by preparation. Mogroside V percentage alone does not guarantee a particular sweetness or cleaner taste: the acute sensory measurements found the tested monk-fruit beverage more bitter and less sweet than the sucrose beverage. Retail blend substitution ratios must come from that product’s directions.
Interactions and evidence gaps
The acute trials reviewed here do not test monk fruit with every medicine. Tey’s study excluded medicines known to affect appetite or glucose/energy metabolism (study population). Check the full ingredient list: blends and herbal preparations contain other substances. Ask a pharmacist about concentrated supplement use alongside medicines; an unstudied combination is not a proven interaction or a safety clearance.
Who should seek advice first
The reviewed trials do not establish concentrated supplementation safety during pregnancy, breastfeeding or childhood. The diabetes-group study excluded pregnancy (original trial); JECFA requests further reproductive-capacity data (2026 recommendations). Ordinary food sweetening must follow the relevant preparation-specific rules. Do not replace prescribed diabetes treatment with monk fruit.
The Kaim and Labus 2025 review declares no external funding and no conflicts, but its numerical trial summaries do not match the original reports. Its references 6 and 9 repeat the same 24-hour-study DOI with inconsistent bibliographic details, and its claimed glucose/insulin benefits disagree with the original IJO trial’s null three-hour totals. DOI 10.3389/fphar.2024.1162883 identifies a mixed-herb pharyngitis-lozenge trial, not the metabolic trial named in the review. Its headline 10–18% glucose and 12–22% insulin reductions should not be used as verified monk-fruit-specific effect sizes.
How laboratory evidence is used
Yeung’s bibliometric analysis describes substantial cell and animal research among the literature’s health claims. It maps publications rather than proving human efficacy. Laboratory mechanisms can motivate clinical trials; they cannot establish a human treatment effect, dose or frequency of benefit. Regulatory safety is a separate question: JECFA’s temporary ADI uses a 52-week rat study with an uncertainty factor.
- Antioxidant mechanisms observed in laboratory or animal studies do not establish a clinical antioxidant benefit from monk fruit supplementation (literature map).
- Animal anti-hyperglycemic or lipid mechanisms cannot be treated as demonstrated human diabetes therapy. The acute beverage results concern different questions (mechanistic literature; human crossover).
- A result in a cell line is not a human treatment trial. It cannot establish how a concentrated product affects normal physiology, pregnancy, medication use or long-term outcomes.
Funding, conflicts and source roles
Research funding at a glance
8 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Source | Declared support / conflicts | Role and remaining limits |
|---|---|---|
| Kaim and Labus 2025 review | No external funding/no conflicts declared | Quantitative trial descriptions conflict with originals; declarations do not validate the results or clear underlying trial finances |
| Yeung 2023 bibliometric analysis | Departmental funds only; absence of commercial/financial relationships declared | Literature map, not clinical efficacy. Departmental backing and included-study finances not fully traced |
| GRN 629 manufacturer dossier | Hunan NutraMax submission via NutraSource; expert panel convened at the manufacturer’s request | Ingredient specifications only. FDA ceased evaluation after withdrawal to change product profiles/specifications; panel payment terms unreported |
| FDA explanation; GRN 627 letter | US regulator explanation and response to a manufacturer-submitted notice | Ingredient/use-specific regulatory assessment, not an efficacy trial or complete financial clearance of underlying safety studies |
| FSAI Article 4 decision, 2 October 2024 | National authority decision published by the European Commission; applicant financial details not in this outcome | Specified non-selective decoction’s novel-food status only; not comparative safety or all extract/additive permission |
| Tey 2017, IJO acute crossover | Singapore Institute for Clinical Sciences/A*STAR; no conflicts declared | Complete relevant accepted manuscript read; definitive full typeset version/supplement not recovered. Product supplier/payment terms and support amounts unreported |
| Tey 2017, EJCN 24-hour study | Singapore Institute for Clinical Sciences/A*STAR; no conflicts declared | Author-uploaded proof read; final full typeset version not recovered. Same trial registration as IJO; participant overlap and product terms not separately reconstructed |
| JECFA 102nd meeting, June 2026; summary issued July 2026 | Joint FAO/WHO process; meeting support from the Government of China, China National Center for Food Safety Risk Assessment and Nanjing Medical University | Primary risk assessment, not human efficacy. Temporary ADI/data requests; underlying toxicology finances and individual financial declarations not fully reconstructed |
Frequently asked questions
Is monk fruit better than stevia for blood sugar?
The ten-person crossover study found no significant 24-hour glucose differences among monk fruit, stevia, aspartame and sucrose beverages. This does not prove equivalence or monk fruit superiority. The three-hour report also found no significant total glucose/insulin AUC difference; neither protocol establishes a long-term diabetes treatment.
Does monk fruit have an official safe daily limit?
Yes. At its June 2026 meeting, JECFA established a temporary ADI of 0–10 mg/kg body weight/day, expressed as mogroside V (WHO record; official summary). It used a 52-week rat NOAEL of 2,144 mg/kg/day and a 200-fold uncertainty factor. A conservative estimate of 38 mg/kg/day for children, based on proposed food categories and maximum use levels, exceeded the temporary ADI by about fourfold and raised a potential concern under those proposed uses. This is not proof of harm from every retail product. Further reproductive-capacity and exposure data are requested by the end of 2029, with additional manufacturing/composition data needed for tentative specifications. The limit is mogroside V mass, not grams of a retail blend, an efficacy dose or automatic national/EU authorisation.
Is monk fruit FDA-approved?
FDA has not questioned GRAS conclusions for certain monk fruit ingredients under their notified conditions of use (FDA explanation). It ceased evaluating GRN 629 after withdrawal to change product profiles/specifications; GRN 627 received a no-questions response for a specific fruit juice concentrate. Neither outcome is blanket FDA approval of every extract or retail product.
Can monk fruit help with weight loss?
The reviewed acute studies do not establish sustained monk-fruit-specific weight loss. In the one-day IJO trial, total daily energy intake did not significantly differ across beverages, and subsequent intake was self-reported. Sugar substitution can reduce the sugar in a product, but this trial cannot establish the long-term effect on body weight.
Is monk fruit safe during pregnancy?
The reviewed clinical trials do not establish pregnancy safety for concentrated extracts; the diabetes-group trial excluded pregnancy. JECFA’s 2026 assessment requests reproductive-capacity data to complete its evaluation. This does not prove harm, and food-use status must be assessed for the specific preparation.
What is the difference between MV 7 and MV 95 grades?
In the SweetMonk manufacturer submission, MV 7 and MV 95 specify minimum mogroside V contents of ≥7% and ≥95% in ingredient powders. These do not describe the concentration of every finished blend. The grade alone does not guarantee cleaner taste, clinical benefit or comparative safety; composition and dilution also matter. GRN 629 was withdrawn, so its presence on FDA’s website is not completed FDA approval.
Sources and funding notes
- Kaim and Labus (2025), systematic review. Bibliographic discrepancies limit confidence; not relied on for quantitative efficacy estimates.
- Hunan NutraMax GRN 629 manufacturer submission — SweetMonk ingredient specifications; FDA withdrawal/cessation letter.
- Yeung 2023 — bibliometric literature analysis; departmental support, no commercial/financial relationships declared. Not a clinical efficacy meta-analysis.
- FDA monk-fruit explanation; GRN 627 agency response; GRN 629 agency response. Preparation-specific US regulatory context.
- FSAI Article 4 decision on non-selective monk fruit decoctions, 2 October 2024. Commission scope guidance
- Tey 2017, International Journal of Obesity — glucose, insulin and energy crossover; accepted author manuscript read; original support and version limits described above.
- Tey 2017, European Journal of Clinical Nutrition — ten-person 24-hour glucose study; author proof read; same registered protocol as IJO, not assumed independent replication.
- Lavalle-Gonzalez 2023, International Journal of Nutrition — acute glucose-load comparison, insulin only in ten non-diabetic controls. Funding unreported/no competing interests declared; no long-term safety certificate.
- Guo 2024 — narrative review of distribution/composition/applications; Macau university and FDCT support, no conflicts declared. Used for botanical context, not human efficacy.
- Xie 2023 — original phylogeographic study, supporting origin of sampled cultivars in Guilin. NSFC and Chinese/Guangxi survey support; no conflicts declared. Not an extract-market census.
- WHO monk-fruit evaluation, 2026; JECFA 102nd meeting official summary and conclusions — temporary ADI, proposed-use exposure concern and further data requests.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.